Compare NXDT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXDT | SPRO |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.0M | 136.7M |
| IPO Year | N/A | 2017 |
| Metric | NXDT | SPRO |
|---|---|---|
| Price | $3.70 | $2.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 133.6K | ★ 342.0K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | N/A | ★ $40,549,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.89 | $0.51 |
| 52 Week High | $13.07 | $3.22 |
| Indicator | NXDT | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 68.15 | 48.42 |
| Support Level | $2.65 | $2.30 |
| Resistance Level | $3.70 | $2.36 |
| Average True Range (ATR) | 0.26 | 0.08 |
| MACD | 0.11 | -0.00 |
| Stochastic Oscillator | 90.04 | 54.17 |
NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. The revenue sources of the company include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates through its operating partnership and wholly owned subsidiaries.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.